With 20+ years of experience in drug development and manufacturing and a global presence with state-of-the-art facilities, we deliver high-quality & customised solutions for complex products.
Eurofins CDMO offers expert drug product development and manufacturing across solid, semi-solid and liquid dosage forms for oral, nasal, buccal, topical, ocular and parenteral delivery.
To improve the solubility and enhance the effectiveness of the drug, our pre-formulation and solid state teams work together using their expertise and proven track record to quickly advance programmes from API through to drug product development.
Particle size reduction
SEDDS (Self-Emulsifying Drug Delivery System) / SMEDDS (Self Microemulsifying Drug Delivery System) Formulation
Spray Drying
Our Highway to Clinic platform offers a comprehensive approach, screening different drug product innovative formulation technologies, to overcome bioavailability enhancement.
Focusing on understanding the physical and chemical properties of the drug molecule (e.g. solubility, stability, polymorphism) and testing the interaction between the drug substance and excipients. In collaboration with our solid-state R&D experts, we assess solubility and rank drug candidates to optimise bioavailability.
Based on pre-formulation data, various formulation strategies are explored based on a quality by design approach to develop a stable and effective drug product. This involves selecting appropriate excipients and dosage forms (dependent on the drug’s characteristics and intended route of administration), to achieve the desired drug release profile, stability, and manufacturability
At Eurofins CDMO, we specialise in developing innovative formulations that provide solutions to enhance bioavailability (e.g. Highway to clinic platform for poorly soluble compounds) and control drug release (e.g colon targeting), especially for challenging-to-formulate drug candidates:
Eurofins CDMO has different state-of-the-art coating techniques carried out in-house (fluid bed coating, drum coating) to formulate coated drug products with a colon targeted release.
Our core focus is GMP clinical drug product manufacturing. Our state-of-the-art facilities and GMP compliant systems are specifically designed for quick-to-clinic operations. We specialise in process transfer and scale-up strategies, providing a seamless transition of programmes from development through to later stage manufacturing.
Comprehensive documentation of all formulation development activities and data, preparing regulatory submissions
